Rare eye condition prompts new FDA warning on popular GLP-1 drugs
The U.S. Food and Drug Administration (FDA) is requiring makers of Ozempic, Wegovy and similar drugs to warn of a rare eye condition that can cause vision loss.
3 hours ago
0
1
Amino Acid, Peptide, or Protein: Semaglutide
Medical news and research articles
Semaglutide may lower fetal oxygen levels, sheep study suggests
They're the blockbuster drugs transforming weight loss, helping millions of people to shed unwanted kilograms. But while medications such as Ozempic and Wegovy may also improve women's chances of becoming pregnant, what happens ...
15 hours ago
0
6
Bariatric surgery is effective rescue strategy after GLP-1 receptor agonist failure
Bariatric surgery is associated with clinically meaningful two-year weight loss after semaglutide or tirzepatide intolerance or inadequate response, according to a study published online Nov. 3 in the Annals of Surgery.
Nov 6, 2026
0
17
Why people trust weight‑loss drug advice on social media, even when it may be misleading
Imagine scrolling through social media and seeing dramatic weight-loss results from people taking Mounjaro, Wegovy or Ozempic. They share photographs, discuss side effects and recommend ways to get the best results.
Nov 3, 2026
0
3
Started a GLP‑1 drug like Ozempic or Mounjaro? Here's what you need to know about nutrition
Around half a million Australians use GLP-1 medications for diabetes—and when you add people who use them for obesity and weight-related conditions, the total is much higher.
Oct 21, 2026
0
12
Hormone therapy may increase weight-loss effectiveness of GLP-1s
The success stories of GLP-1 weight-loss medications are dominating the airwaves. Midlife women, who commonly experience weight gain resulting from menopause, have been especially drawn to the drugs.
Oct 20, 2026
0
10
Weight loss drugs may protect against heart failure
Weight-loss drugs known as GLP-1s may help protect against heart failure even at doses too low to produce significant weight loss, according to a laboratory study led by Cedars-Sinai Health Sciences University investigators.
Oct 14, 2026
0
11
Trevogrumab (anti-myostatin) can help preserve lean mass during and after semaglutide-induced weight loss
New research presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28–Oct. 2, and in press at The Lancet shows that trevogrumab, which inhibits a protein that ...
Sep 30, 2026
0
191
Higher GLP-1 costs lead to lower adherence
Semaglutides, or GLP-1s, can produce substantial weight loss if individuals adhere to their doctor's instructions. But a new study from the University of Georgia suggests patients aren't taking the weight loss medication ...
Sep 30, 2026
0
9
Regulator-mandated study finds no link between semaglutide use and pancreatic cancer
New research presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28–Oct. 2, found no link between semaglutide use and pancreatic cancer in nationwide registry ...
Sep 28, 2026
0
21
